The Renal Biopsy & Its

The contract between this chapter and the reader.

1. 1. State the indications for renal biopsy.
2. 2. Describe the biopsy procedure and pre-biopsy preparation.
3. 3. Recognise and prevent the complications.
4. 4. Describe the three microscopies and what each shows.
5. 5. Use immunofluorescence to identify the mechanism.
6. 6. Use electron microscopy for deposits and the podocyte/GBM.
7. 7. Integrate the three microscopies to reach a diagnosis.
8. 8. Distinguish activity from chronicity.

A sixty-second reading. Each bullet stands alone.

• The renal biopsy is the definitive diagnostic test for glomerular disease.
• It is indicated for unexplained nephrotic or nephritic disease, rapidly progressive GN, unexplained AKI, and suspected systemic disease.
• It is performed percutaneously under ultrasound guidance with a spring-loaded needle.
• Before biopsy, coagulation, platelets, and blood pressure are checked and antithrombotics stopped.
• Bleeding is the main complication — usually minor haematuria, occasionally a hematoma or an arteriovenous fistula.
• The biopsy is read by three complementary microscopies: light, immunofluorescence, and electron.
• Light microscopy shows architecture — proliferation, sclerosis, crescents, and necrosis.
• Immunofluorescence shows the immune deposits and their pattern — granular, linear, pauci-immune, or mesangial.
• Electron microscopy shows deposit location, foot-process effacement, and the basement membrane.
• No single microscopy suffices; they are integrated to reach the diagnosis.
• The biopsy distinguishes active, treatable lesions from chronic, irreversible scarring.
• Adequacy — enough glomeruli — is needed for a reliable result.

The medical core. An expert should agree the renal biopsy and its interpretation are fully covered here.

Why it matters at the bedside

The biopsy is where the syndrome becomes a diagnosis. A few millimetres of cortex, read under three microscopes, can turn ‘nephrotic syndrome’ into ‘membranous nephropathy with active subepithelial deposits’ — and so decide whether to immunosuppress, how hard, and what to expect. Knowing when to take it, how to take it safely, and how to read it is the diagnostic heart of this volume.

Why and when to biopsy

• The renal biopsy is the definitive diagnostic test: it confirms the diagnosis, grades the balance of activity and chronicity that guides treatment and prognosis, and can monitor disease. Its indications (the approach chapter) are unexplained nephrotic or nephritic disease, rapidly progressive glomerulonephritis (urgently), unexplained acute kidney injury, suspected systemic disease, and — across the trilogy — transplant dysfunction. The governing rule is to biopsy when the result would change management.

The procedure and preparation

• A native biopsy is performed percutaneously under real-time ultrasound guidance, sampling the lower pole of the kidney with a spring-loaded needle to obtain cores containing enough glomeruli for all three microscopies. Preparation is about safety: checking and correcting coagulation and platelets, controlling blood pressure, and stopping antiplatelet and anticoagulant drugs beforehand. Afterwards the patient rests and is monitored for bleeding.

The complications

• Bleeding is the dominant risk. Most is minor — transient haematuria — but a perinephric hematoma can occur and, rarely, significant bleeding requires transfusion, embolization, or surgery; an arteriovenous fistula may form (usually managed conservatively). Pain is common and minor; infection is rare; nephrectomy and death are very rare. Risk rises with uncontrolled blood pressure, coagulopathy, low platelets, and a small or single kidney — which is why the pre-biopsy check matters.

The three microscopies

• The biopsy is read by three complementary techniques, and the diagnosis emerges only from their combination. Light microscopy shows the tissue architecture; immunofluorescence shows the immune deposits and their pattern; and electron microscopy shows the ultrastructure. Each answers a different question, and no one of them suffices alone.

Light microscopy

• Light microscopy — with its panel of stains (H&E, PAS, silver, trichrome) — reveals the glomerular architecture: cellular proliferation, sclerosis, crescents, necrosis, and basement-membrane changes. It establishes the distribution (focal versus diffuse, segmental versus global) and, crucially, the balance of active and chronic lesions that drives treatment decisions.

Immunofluorescence

• Immunofluorescence stains for immunoglobulins (IgG, IgA, IgM), complement (C3, C1q), and light chains (kappa, lambda), revealing what is deposited and in what pattern — granular (immune-complex), linear (anti-GBM), pauci-immune (ANCA), or mesangial (IgA). This is the technique that reads the mechanism off the tissue, linking the biopsy directly to the injury categories of the first chapter.

Electron microscopy

• Electron microscopy resolves the ultrastructure: the precise location of immune deposits (subepithelial, subendothelial, mesangial), the state of the podocyte foot processes (effacement in proteinuric disease), and the basement membrane (thin, thickened, or split, as in Alport). It is indispensable for the podocytopathies, for localising deposits, and for the organised deposits of amyloid and fibrillary disease.

Reading the biopsy: integrating the three

• Diagnosis is pattern recognition across all three. Foot-process effacement with normal light microscopy and negative immunofluorescence is minimal change; subepithelial deposits with granular IgG/C3 and GBM spikes are membranous; segmental sclerosis is FSGS; mesangial IgA is IgA nephropathy; linear IgG with crescents is anti-GBM; pauci-immune crescents are ANCA; ‘full-house’ staining (all immunoglobulins plus complement) is lupus; and Congo-red-positive fibrils are amyloid. The three views converge on a single name.

Activity versus chronicity

• Beyond the diagnosis, the biopsy answers a treatment question: how much of the damage is active and how much is chronic. Active lesions — cellular crescents, necrosis, proliferation, inflammation — are treatable and justify immunosuppression; chronic lesions — global sclerosis, fibrous crescents, interstitial fibrosis and tubular atrophy — are irreversible and predict limited recovery. Reading that balance tells you whether, and how aggressively, to treat.

Five fully-built tables.

Table A — Indications

Table B — Procedure and preparation

Table C — Complications

Table D — The three microscopies

Table E — Pattern recognition

Visualise & Map

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Five cases. Each stops you at a decision before it answers it.

Exhaustive. Every rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — Pre-biopsy safety checklist note

• Indication and that the result will change management: ___.
• Coagulation / platelets checked and adequate; antithrombotics stopped: ___.
• Blood pressure controlled: ___.
• Anatomy (single kidney / size) and approach (percutaneous vs transjugular): ___.
• Consent; post-biopsy monitoring plan for bleeding: ___.

Template 2 — Biopsy interpretation note

• Adequacy: number of glomeruli; tissue for LM/IF/EM: ___.
• Light microscopy: proliferation/sclerosis/crescents/necrosis; distribution ___.
• Immunofluorescence: deposits and pattern (granular/linear/pauci/mesangial) ___.
• Electron microscopy: deposit location; foot processes; GBM ___.
• Integrated diagnosis; activity vs chronicity; treatment implication ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Eight items, each anchored in this chapter. At least one per objective.